
## Javier SÃ;nchez RamÃ-rez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8742968/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Potential mechanisms involved on how systemic IgG antibodies specific to vascular endothelial growth factor (VEGF) and induced by active immunotherapy decrease platelet derived free-VEGF. Platelets, 2022, , 1-5.	2.3	0
2	Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program. BMC Immunology, 2020, 21, 12.	2.2	5
3	Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels?. BMC Research Notes, 2019, 12, 323.	1.4	10
4	Specific active immunotherapy with the HEBERSaVax VEGF-based cancer vaccine: From bench to bedside. Seminars in Oncology, 2018, 45, 68-74.	2.2	11
5	Evaluation of methodologies to determine the effect of specific active immunotherapy on VEGF levels in phase I clinical trial patients with advanced solid tumors. Heliyon, 2018, 4, e00906.	3.2	7
6	Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine. Vaccine, 2017, 35, 3582-3590.	3.8	30
7	Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants. BMC Immunology, 2017, 18, 39.	2.2	10
8	Indirect and competitive enzyme-linked immunosorbent assays for monitoring the humoral response against human VEGF. Journal of Immunoassay and Immunochemistry, 2016, 37, 636-658.	1.1	7
9	Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates. Vaccine, 2012, 30, 368-377.	3.8	21